1. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production
- Author
-
Alain, Tommy, Lun, XueQing, Martineau, Yvan, Sean, Polen, Pulendran, Bali, Petroulakis, Emmanuel, Zemp, Franz J., Lemay, Chantal G., Roy, Dominic, Bell, John C., Thomas, George, Kozma, Sara C., Forsyth, Peter A., Costa-Mattioli, Mauro, and Sonenberg, Nahum
- Subjects
Stomatitis -- Diagnosis ,Gliomas -- Care and treatment ,Rapamycin -- Health aspects ,Science and technology - Abstract
Oncolytic viruses constitute a promising therapy against malignant gliomas (MGs). However, virus-induced type I IFN greatly limits its clinical application. The kinase mammalian target of rapamycin (mTOR) stimulates type I IFN production via phosphorylation of its effector proteins, 4E-BPs and S6Ks. Here we show that mouse embryonic fibroblasts and mice lacking $6K1 and S6K2 are more susceptible to vesicular stomatitis virus (VSV) infection than their WT counterparts as a result of an impaired type I IFN response. We used this knowledge to employ a pharmacoviral approach to treat MGs. The highly specific inhibitor of mTOR rapamycin, in combination with an IFN-sensitive VSV-mutant strain ([VSV.sup.[DELRAM5l]), dramatically increased the survival of immunocompetent rats bearing MGs. More importantly, [VSV.sup.[DELTAM51] selectively killed tumor, but not normal cells, in MG-bearing rats treated with rapamycin. These results demonstrate that reducing type I IFNs through inhibition of mTORCl is an effective strategy to augment the therapeutic activity of [VSV.sup.[DELTA]M51]. innate antiviral immunity | malignant gliomas | mTORC1 | oncolytic viruses doi/ 10.1073/pnas.0912344107
- Published
- 2010